Edition:
India

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

23.46USD
2:29am IST
Change (% chg)

$0.32 (+1.38%)
Prev Close
$23.14
Open
$23.32
Day's High
$23.60
Day's Low
$23.04
Volume
3,104
Avg. Vol
6,594
52-wk High
$28.99
52-wk Low
$15.31

Chart for

About

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $197.28
Shares Outstanding(Mil.): 8.88
Dividend: --
Yield (%): --

Financials

BRIEF-Albireo posts Q3 loss per share $0.73‍​

* Albireo Pharma Inc - ‍decision on potential approval of elobixibat in Japan expected in first half of 2018​

14 Nov 2017

BRIEF-Albireo Pharma to present final results of phase 2 study of A4250 in children with cholestatic liver disease

* Final results of Albireo’s phase 2 study of A4250 in children with cholestatic liver disease presented at the liver meeting 2017

20 Oct 2017

BRIEF-Albireo Pharma files for mixed shelf of up to $125 million‍​

* Albireo Pharma Inc files for mixed shelf of up to $125 million - SEC filing‍​ ‍​ Source text for Eikon: (http://bit.ly/2i8yKC7) Further company coverage:

14 Oct 2017

BRIEF-Albireo elects Roger Jeffs to board of directors

* Albireo Pharma Inc - ‍Jeffs replaces Denise Scots-Knight, who is departing from board​ Source text for Eikon: Further company coverage:

28 Sep 2017

BRIEF-EMA paediatric committee agrees to Albireo's A4250 pediatric investigation plan

* EMA's paediatric committee agrees to Albireo’s a4250 pediatric investigation plan

26 Sep 2017

BRIEF-Albireo Pharma Q2 loss per share $0.86

* Albireo Pharma Inc - qtrly net loss per share diluted $0.86

21 Aug 2017

BRIEF-Albireo Pharma files non-timely 10-K‍​

* Albireo Pharma - unable to file 10-Q quarter ended June 30, 2017 in time due to unexpected delay in preparation of unaudited interim financial statements

15 Aug 2017

Earnings vs. Estimates